- Research article
- Open Access
The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients
BMC Psychiatry volume 13, Article number: 127 (2013)
The Screen for Cognitive Impairment in Psychiatry (SCIP) is a simple and easy to administer scale developed for screening cognitive deficits. This study presents the diagnostic-specific standardization data for this scale in a sample of schizophrenia and bipolar I disorder patients.
Patients between 18 and 55 years who are in a stable phase of the disease, diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder were enrolled in this study.
The SCIP-S was administered to 514 patients (57.9% male), divided into two age groups (18–39 and 40–55 years) and two educational level groups (less than and secondary or higher education). The performance of the patients on the SCIP-S is described and the transformed scores for each SCIP-S subtest, as well as the total score on the instrument, are presented as a percentile, z-score, T-scores, and IQ quotient.
We present the first jointly developed benchmarks for a cognitive screening test exploring functional psychosis (schizophrenia and bipolar disorder), which provide increased information about patient’s cognitive abilities. Having guidelines for interpreting SCIP-S scores represents a step forward in the clinical utility of this instrument and adds valuable information for its use.
Cognitive deficits are highly prevalent in psychotic disorders , including schizophrenia, bipolar disorder, and schizoaffective disorder [2–6]. Numerous studies suggest that patients with severe psychiatric disorders have impaired sustained attention  and memory [8–10]. A wide spectrum of executive deficits have also been described, including problems performing goal-oriented tasks, recognizing priority patterns, and planning [11, 12], along with diminished verbal fluency  and information processing speed [14, 15]. Increasing recognition that psychosocial prognosis is directly related to the severity of the cognitive impairments [16–19], has resulted in a paradigm shift that may expand the targets for treatment beyond the mere symptom suppression and necessitate an integration of cognitive assessment into routine psychiatric practice.
The importance on the field of this study is emphasized by a long-standing initiative of the National Institute of Mental Health, known as MATRICS [20, 21], which has now been subdivided into three different programs: CNTRICS , TURNS , and TENETS (Treatment and Evaluation Network for Trials in Schizophrenia). The aim of these initiatives is to unify and standardize the types of deficits to be measured and the tests to use, with the final objective of developing effective new treatments for the neurocognitive deficits that occur in these patients. Recently, the MATRICS initiative has proposed a consensus battery that takes between 60 and 90 minutes to administer and is composed of 10 paper-and-pencil tests specifically for cognitive assessment of patients with schizophrenia – the MATRICS Consensus Cognitive Battery [24, 25]. Given the difficulties of performing an assessment lasting more than one hour in standard clinical practice, in the past few decades, considerable effort has been made to create brief cognitive batteries that facilitate an overall understanding of the individual’s cognitive status, without overly sacrificing the sensitivity and specificity of these new instruments. Some examples are the Cognistat, before 1995 known as the Neurobehavioral Cognitive Status Examination , the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) , the Woodcock-Johnson III Test of Cognitive Abilities (WJ III COG) , and the Brief Assessment of Cognition in Schizophrenia (BACS) . These instruments have decreased the time it takes to assess patients to about 40–50 minutes, but even so they have a high cost in terms of time and economics due to time constraints on practitioners in their daily clinical practice.
More recently, other types of studies have focused on the development of cognitive screening tools – scales that do not require additional materials in order to be administered, tools that have different interchangeable versions, tools that are simple and easy to administer, and have an administration time that is appropriate and manageable in clinical practice, i.e., approximately 15 minutes. Some examples are the Brief Cognitive Assessment (BCA) , the Screen for Cognitive Impairment in Psychiatry (SCIP) , and the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) . All of these have good psychometric properties [30–35], but still no standardization data have been established for any of them.
A Spanish translation of the SCIP was recently introduced (SCIP-S)  which demonstrated appropriate psychometric properties both for patients with a diagnosis of schizophrenia  and those with bipolar I disorder , with regard to equivalence between parallel forms, internal consistency, temporal stability, dimensional structure, and convergent validity. Tentative cut-scores for identification of significant cognitive impairment irrespective of diagnosis are available , but the resulting binary classification is insufficient for description of the severity of identified impairment relative to a patient’s clinical cohort after adjustment for age, gender, and education. Guidelines for the interpretation of the SCIP-S would thus represent a step forward in the clinical utility of this instrument and add valuable information on its proper use.
Normative data represent performance on a measure or test by a standardization sample against which other performances on the measure can be compared . Lack of normative data limits the interpretation of scores in individual cases as well as in treatment outcome research (as we cannot know if a score is typical, high or low for the population being studied) . This has implications for our ability to assess the clinical significance of a score (or change in a score). Norm scores can assist clinicians in providing quantitative labels for the degree to which a raw score is to be considered average, elevated, or extreme and might be useful for diagnostic purposes, clinical decision making, or evaluation of treatment effects . A traditional approach to deriving norm scores is to compare an individual’s raw score to a reference group with the same condition matched for background variables such as age and gender. In addition, clinicians using norms for comparison can more readily interpret a patient’s performance on a number of relevant self-report dimensions as well. This should assist in the determination of whether or not an individual’s responses are unusual for someone experiencing, in this case, cognitive deficits. In turn, this may suggest possible courses of action, such as further investigation or treatment (whose outcome can be evaluated against the normative dataset) [37, 38].
When evaluating cognitive function in routine practice, clinicians usually compare the patient score against the norms in the general healthy population to ascertain whether the patient cognitive function is preserved or impaired. In such case, comparison allows to determine the distance to what a particular patient separate from the mean score. Nevertheless, in many cases the practitioner refers the patient to a specialist for formal recognition when his/her performance is unusually low compared with patients with same condition. Particularly when additional etiologies (in addition or replacement of schizophrenia) responsible for the high cognitive impairment observed is suspected . Concerning this point, patient score should be compared with the norms belonging to subjects with the same health condition to assess how the different is the patient scoring related to his/her population of reference. As stated by Irvison et al. , this information can improve the clinician´s understanding of patient´s cognitive strength and weakness, put a patient’s cognitive abilities into perspective for their diagnosis, and facilitate multidisciplinary treatment decisions.
In this context, to date there are no standardization data for the SCIP-S scale in psychiatric patients that allow the examiner to interpret the patient scores relative to the cognitive performance of their peers. Thus, the objective of this study is to provide the first clinical normative data for the SCIP-S in patients with functional psychosis, and specifically with schizophrenia-spectrum disorder or bipolar I disorder.
Patients diagnosed criteria with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder according to DSM-IV-TR  were enrolled in this study. To take part, patients had to be between 18 and 55 years of age and in a stable phase of the disease. In the case of patients with schizophrenia spectrum disorders, stability was defined by: a) no hospitalization in the past 3 months, and b) a total score of less than 70 on the Positive and Negative Syndrome Scale (PANSS) [42, 43]. In the case of patients with bipolar I disorder, stability was defined as: a) 6 or more months in remission, b) a score less than or equal to 7 on the 17-items Hamilton Depression Scale (HAM-D) , and c) a score less than or equal to 6 on the Young Mania Rating Scale (YMRS) . We excluded individuals that were participating in a clinical trial, and those with a serious medical or neurological condition, another psychiatric disorder as a primary diagnosis or main reason for treatment, major depression, or difficulty reading and/or writing. The process of recruitment began with a consensus conference on the diagnostic criteria for the different schizophrenia spectrum disorders and the bipolar disorder I. This consensus was adopted by all participating psychiatrists. This conference dealt mainly with the standard psychiatric interview based on the DSM-IV diagnostic criteria (anamnesis and the exploration of the mental condition), the PANSS, HAM-D, and YMRS scales, and the different inclusion/exclusion criteria of our study.
The SCIP  is a brief screening tool designed to assess cognitive impairment in psychiatric patients. It has five subtests for evaluating immediate (Verbal Learning Test-Immediate; VLT-I) and delayed (Verbal Learning Test-Delayed; VLT-D) verbal learning, working memory (Working Memory Test; WMT), verbal fluency (Verbal Fluency Test; VFT), and processing speed (Processing Speed Test; PST). It may be administered without the need for additional equipment, i.e., a pencil and a stopwatch, and requires nearly 15 min. Three alternative forms of the scale are available to facilitate repeated testing. Table 1 contains the description and the main characteristics of the SCIP subtests.
The psychometric properties of the SCIP were studied in a sample of patients with schizophrenia  and in a sample of bipolar I patients , and were shown to be adequate. Specifically, both studies demonstrated the equivalence among the three parallel forms, internal consistency (Cronbach’s alpha of 0.73 and 0.74, respectively), and test-retest reliability (intraclass correlation coefficient of 0.90 and 0.87, respectively, for the SCIP total score). Convergent validity was supported by the associations between SCIP subtests and conventional neuropsychological instruments applied in routine clinical practice. The scores also converged on a single cognitive factor accounting for around 50% of the total variance, suggesting a one-factor internal structure in both samples named cognitive performance. Finally, when comparing cognitively-impaired individuals and those with adequate functioning, the proposed cut-off point of the SCIP (< 70) was associated with a sensitivity of 87.9 and specificity of 80.6.
This study was approved by the University of Barcelona Ethics Committee. The SCIP-S was administered to all patients, who were systematically tested once it was confirmed that they met the study inclusion criteria and gave their written informed consent to voluntarily participate in the study; data confidentiality was maintained at all times. The data were collected at 119 Spanish mental health centers, selected by probability sampling adjusted by population weights from the 17 Spanish Autonomous Communities, with the participation of 132 psychiatrists duly trained in administering the instrument with a video designed for that purpose. Before the start of the process, a neuropsychologist experienced in administration of neuropsychological tests and batteries trained a sub-set of forty-four psychiatrists in a 60-minute session to ensure consistency in SCIP administration and correction. The training phase was completed with a kappa index of agreement in scale correction and scoring of .99.
The analyses were done using the SPSS statistical package version 15 and the significance level was set at α = .01. The internal consistency of the SCIP was assessed by computing Cronbach’s alpha coefficient, treating each of the SCIP subtests as variables. We compared the SCIP scores of patients with schizophrenia and bipolar I disorder, as well as between males and females, using a t test for independent samples. In both cases, the statistical significance was supplemented by calculating Cohen’s d. Likewise, the differences between the specified groups were analyzed by age and educational level. The normal distribution of the data was tested using the Kolmogorov-Smirnov (KS) test for normality.
Patient performance on the SCIP was shown using various descriptive statistics (mean, standard deviation, median, asymmetry, kurtosis, and range of scores). As for the transformation of SCIP scores, a percentile, z-score, T-scores (T = 50 + 10 » z), and intelligence quotient (IQ = 100 + 15 » z) were calculated.
A total of 514 patients diagnosed according to DSM-IV-TR  criteria with schizophrenia (41.5%), schizoaffective disorder (6.4%), schizophreniform disorder (1.4%), or bipolar I disorder (50.7%) participated in this study. Within this group, 57.9% were males. Most patients with schizophrenia were being treated with a single antipsychotic (66.9%), although a large number were receiving a combination of two (28.0%) or three (3.1%) antipsychotics. At the time of assessment, 5 patients were not taking any antipsychotic. In addition to the antipsychotic medication, 52.6% of patients were receiving an additional psychoactive drug, primarily antidepressants and benzodiazepines. The mean age at onset of the illness was 24.25 (SD = 6.34), the mean number of months since the diagnosis was 156.78 (102.99), and the mean number of hospitalizations was 2.61 (3.05). Within the bipolar I disorder sample, 23.5% were taking lithium, while other patients were taking one (33.5%) or two (3.5%) antipsychotics in addition to lithium, and finally another group of patients were taking receiving antipsychotic medication in monotherapy (23.8%), or in a combination of two (5.0%), or three (0.4%) agents. Additionally, 75.4% of patients were receiving another type of psychoactive drug (i.e., antidepressants or benzodiazepines). The mean age at onset of the illness was 28.39 (8.34), the mean number of months since the diagnosis was 144.55 (95.78), the mean number of manic episodes they had experienced was 3.36 (1.86), and of depressive episodes was 1.22 (2.94), and finally the mean number of hospitalizations was 2.80 (3.67).
The participants were divided into two age groups (18–39 and 40–55) and two education level groups (less than secondary education and secondary education or higher). Based on these and other variables, Table 2 shows the main demographic information for each clinical sample used in the study.
Comparison between groups
By comparing the scores of patients with schizophrenia and bipolar disorder I, as well as between men and women, we obtained the means, standard deviations, t statistics, and effect sizes specified in Table 3.
Both in the various subtests and in the total score, the mean performance of the patients with schizophrenia was poorer than that of the patients with bipolar I disorder, although in no case was the effect size measurement significant. With respect to sex, the mean scores were similar, with the exception of the VLT-D subtest, where women scored slightly better than men, although the corresponding effect size was small. As was to be expected, on all subtests, as well as on the total SCIP score, the patients with a higher education scored higher than those with a less than secondary education (all p values < .01), with effect sizes that varied between 0.50 for the VFT subtest and 0.70 for the PST subtest. The difference in total SCIP score, for the education variable, reached an effect size of 0.78. In the case of age, as the patients’ age increases, the mean scores decreased. The differences were statistically significant (p value < .01) for the total SCIP score and the various subtests, with the exception of the VLT-I and VFT. The effect sizes varied between 0.25 for the VLT-I subtest and 0.54 for the PST subtest, while the difference in total SCIP score was characterized by having an effect size of 0.53. For those reasons, the clinical normative benchmarks are presented jointly for male and female patients with schizophrenia and bipolar I disorder. On the other hand, given the existing differences, patient age and educational level were taken into account.
The internal consistency of the SCIP achieved a Cronbach’s alpha coefficient of 0.73, which is an acceptable value given the small number of variables. This alpha value did not increase when any of the component variables were eliminated. The item/scale correlations were between 0.44 for the VFT and 0.58 for the PST. The normal distribution of the data from the various subtests (and total SCIP-S score) was tested for each of the groups after combining the two age groups and the two participant educational level groups. In no case was the KS test statistically significant at a level of 0.01 (all p > .01) although in six cases there were p values below .05 (the WMT, VFT, VLT-D, and PST subtests in the 18–39 year old group and the VLT-D and PST subtests in the 40–55 year old group, in all cases with a secondary or higher education). Tables 4, 5, 6, 7 and 8 show the clinical normative data for each of the SCIP-S subtests in terms of percentiles, z-scores, T-scores, and IQ. Likewise, Table 9 shows this same information for the total SCIP-S score.
After administering the instrument, for norming the cognitive performance of a patient with schizophrenia or bipolar I disorder against the reference or comparator group, the examiner has only to locate the corresponding transformed score on the table by the patient’s age and educational level.
The clinical value of a screening tool is directly related to either considering cognitive impairment a key aspect of schizophrenic psychopathology and, according to the proposed DSM-V revisions, recommending it as one key dimension to be measured in all patients with a psychotic disorder, or including cognitive deficit as one of the diagnostic criteria for psychoses as suggested by some authors [46, 47]. The practical utility of the administered tests should not be forgotten when conducting a neuropsychological assessment, and since there is a large number of psychiatric patients (accounting for around 2% of the general population) who require diagnosis, there is a growing need for cost-effective and highly efficient diagnostic tools. In this regard, the creation of the SCIP-S precisely had these two objectives. Previous studies [33, 34] have shown that the SCIP-S takes approximately 15 minutes to administer, compared to a mean of around 75 minutes for the administration of a full neuropsychological battery or between 60–90 minutes for the MCCB, and it has good validity and reliability. Furthermore, Rojo et al.  reported the good sensitivity and specificity of the test and its high diagnostic value for appropriately distinguishing cognitively preserved from cognitively impaired individuals.
This study goes a step farther and presents the diagnostic-specific norms and performance for the SCIP-S according to the age and educational level of subjects in a large sample of patients with schizophrenia and bipolar disorder. Some studies report differences in neuropsychological performance between subjects with different educational levels [48, 49], and such differences were also found in this study, which is why in the SCIP-S standardization data the sample has been divided based on educational level. It should be pointed out that, although there is not always a direct correspondence between educational level and years of education, we may consider that in the vast majority of cases a less than secondary education implies fewer than 12 years of education, while a secondary or higher educational level implies at least 12 years of education.
Another aspect known to influence cognitive performance is age, as over the years a series of cortical changes occurs resulting in a loss of brain volume [50, 51] associated with a decrease in cognitive performance in the general population [52, 53]. Our norms take this aspect into account by dividing the sample according to age and limiting patient age to 55 years in order not to introduce bias due to patients whose performance could be affected by early onset of a picture of dementia.
One item that bears emphasizing refers to that fact that a certain pattern was observed to repeat in the various subtests and total SCIP-S score. Specifically, the median score in the two age groups is similar (a maximum difference of 1 point) when the patients have a high educational level, while differences of up to 8 points are found in the groups with a primary or lower educational level. This may be explained by an interaction between age and educational level and the possibility that age at onset of illness plays an important role, since some studies show that both verbal intelligence and impairment of verbal memory and executive functioning could be affected in patients before they experience their first psychotic episode [54–56], such that the earlier the onset of illness, the greater the potential for limiting the patient’s ability to normally pursue an education. Therefore, the effects of age and educational level and their interaction were explored by adding age at onset of illness as a covariate. Such interaction was not statistically significant in any SCIP-S score (all p > .01).
One of the aspects highlighted by this study is that of all the tests mentioned above that have been developed for the purposes of cognitively assessing psychiatric patients, we find diagnosis-specific standardization data for patients with schizophrenia only for the RBANS [39, 40]. And as stated by Iverson et al. , being able to describe a patient’s cognitive performance in terms of expectation for their peer group is more useful to multidisciplinary treatment teams than just comparing them to a healthy population. So the present study provides the tools necessary to interpret the score obtained by a patient with functional psychosis relative to other patients after administration of the SCIP-S scale. As an example, let us apply the SCIP-S to an imaginary 38 year old college graduate diagnosed with schizophrenia who obtains a direct score of 13 on the WMT subtest. After determining their performance relative to healthy controls (healthy control norms are under elaboration), the clinician interest could move to answer the question: Where do we situate that individual with respect to other patients? Looking at Table 4, we see that, based on his age and educational level, this patient is in the 9th percentile, has a z-score of −1.45, a T-score of 36, and an IQ of 78. This tells us that only 9% of his comparison group has obtained a score below his and that his working memory score of 13 is situated approximately 1.5 standard deviations below the other patients.
The SCIP and the SCIP-S provides a quick and convenient cognitive diagnosis and, in that regard, its usefulness extends to areas such as detection, cognitive assessment of large samples, epidemiological and screening diagnostic studies more than to specific cognitive domains or type of impairment in patients with functional psychosis. In that way, it is a complementary test that is not intended to replace complete neuropsychological batteries. Future studies should explore how performance on the SCIP relates to other cognitive domains that it does not measure directly (e.g., problem solving, social cognition, etc.).
A study that could continue this one should be perform standardization data for patients over 55 years of age, since, at a cognitive level, that is a critical age where the SCIP-S could help us reach a differential diagnosis between onset of dementia versus cognitive dysfunction associated with functional psychosis. Future research with this scale should also incorporate the development of guidelines for interpreting the scoring according to results of treatment of patients. Additionally, last evidences in schizophrenic and bipolar patients from recent studies have suggested that the history of psychosis explain part of the neurocognitive performance , thus in future studies with cognitive screening tools would be interesting to take this variable into account.
In short, this study presents the first jointly developed diagnostic-specific norms for the SCIP for functional psychosis (schizophrenia and bipolar disorder), providing increased information about their cognitive abilities.
Jakobsen KD, Hansen T, Werge T: Diagnostic stability among chronic patients with functional psychoses: an epidemiological and clinical study. BMC Psychiatry. 2007, 7: 41-10.1186/1471-244X-7-41.
Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998, 12: 426-445.
Krabbendam L, Arts B, van Os J, Aleman A: Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005, 80: 137-149. 10.1016/j.schres.2005.08.004.
Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos R, Balanzá-Martínez V, Salazar-Fraile J, Selva-Vera G, Vieta E: Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom. 2006, 75: 72-84. 10.1159/000090891.
Cuesta MJ, Peralta V, Zarzuela A: Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis. Schizophr Res. 2007, 95: 39-47. 10.1016/j.schres.2007.06.021.
Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, Bromet E: Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009, 35: 1022-1029. 10.1093/schbul/sbn044.
Francey SM, Jackson HJ, Phillips LJ, Wood SJ, Yung AR, McGorry PD: Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophr Res. 2005, 79: 127-136. 10.1016/j.schres.2005.06.023.
Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P: Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991, 48: 618-624. 10.1001/archpsyc.1991.01810310036007.
Tamminga CA, Stan AD, Wagner AD: The hippocampal formation in schizophrenia. Am J Psychiatry. 2010, 167: 1178-1193. 10.1176/appi.ajp.2010.09081187.
Studentkowski G, Scheele D, Calabrese P, Balkau F, Höffler J, Aubel T, Edel MA, Juckel G, Assion HJ: Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia. Eur J Med Res. 2010, 15: 70-78.
Greenwood KE, Morris R, Sigmundsson T, Landau S, Wykes T: Executive functioning in schizophrenia and the relationship with symptom profile and chronicity. J Int Neuropsychol Soc. 2008, 14: 782-792.
Basso MR, Lowery N, Ghormley C, Ward T, Purdie R, Neel J, Combs DR, Bornstein RA: Neuropsychological impairment and psychosis in mania. J Clin Exp Neuropsychol. 2009, 31: 523-532. 10.1080/13803390802304516.
Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH: Verbal fluency as a possible predictor for psychosis. Eur Psychiatry. 2010, 25: 105-110.
Bonner-Jackson A, Grossman LS, Harrow M, Rosen C: Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge. Compr Psychiatry. 2010, 51: 471-479. 10.1016/j.comppsych.2010.02.005.
González-Blanch C, Rodríguez-Sánchez JM, Pérez-Iglesias R, Pardo-García G, Martínez-García O, Vázquez-Barquero JL, Crespo-Facorro B: First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing. Schizophr Res. 2010, 119: 18-26. 10.1016/j.schres.2010.02.1072.
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996, 153: 321-330.
Harvey PD, Sharma T: Understanding and treating cognition in schizophrenia: A clinician’s handbook. 2002, London: Dunitz
Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martinez-Aran A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gómez-Beneyto M, Vieta E: Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord. 2008, 109: 286-299. 10.1016/j.jad.2007.12.234.
Simonsen C, Sundet K, Vaskinn A, Ueland T, Romm KL, Hellvin T, Melle I, Friis S, Andreassen OA: Psychosocial function in schizophrenia and bipolar disorder: relationship to neurocognition and clinical symptoms. J Int Neuropsychol Soc. 2010, 28: 1-13.
Green MF, Nuechterlein KH: The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004, 72: 1-3. 10.1016/j.schres.2004.09.006.
Kern RS, Green MF, Nuechterlein KH, Deng BH: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res. 2004, 72: 11-19. 10.1016/j.schres.2004.09.004.
Carter CS, Barch DM: Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007, 33: 1131-1137. 10.1093/schbul/sbm081.
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007, 33: 1120-1130. 10.1093/schbul/sbm083.
Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR: The MATRICS consensus cognitive battery, part 2: co-norming and standardization. Am J Psychiatry. 2008, 165: 214-220. 10.1176/appi.ajp.2007.07010043.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR: The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008, 165: 203-213. 10.1176/appi.ajp.2007.07010042.
Kiernan RJ, Mueller J, Langston JW, Van Dyke C: The neurobehavioral cognitive status examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med. 1987, 107: 481-485. 10.7326/0003-4819-107-4-481.
Randolph C, Tierney MC, Mohr E, Chase TN: The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998, 20: 310-319. 10.1076/jcen.20.3.310.823.
Woodcock RW, McGrew KS, Mather N: Woodcock-Johnson III tests of cognitive abilities. 2001, Itasca, IL: Riverside
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L: The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004, 68: 283-297. 10.1016/j.schres.2003.09.011.
Velligan DI, DiCocco M, Bow-Thomas CC, Cadle C, Glahn DC, Miller AL, Biggs MM, Shores-Wilson K, McKenzie CA, Crismon ML: A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res. 2004, 71: 273-283. 10.1016/j.schres.2004.02.027.
Purdon SE: The Screen for Cognitive Impairment in Psychiatry (SCIP): Instructions and three alternate forms. 2005, PNL Inc, Edmonton: Alberta
Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM: A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011, 37: 538-545. 10.1093/schbul/sbp095.
Guilera G, Pino O, Gómez-Benito J, Rojo JE, Vieta E, Tabarés-Seisdedos R, Segarra N, Martínez-Arán A, Franco M, Cuesta MJ, Crespo-Facorro B, Bernardo M, Purdon SE, Díez T, Rejas J, on behalf of the Spanish Working Group in Cognitive Function: Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health Qual Life Outcomes. 2009, 7: 28-10.1186/1477-7525-7-28.
Pino O, Guilera G, Rojo E, Gómez-Benito J, Bernardo M, Crespo-Facorro B, Cuesta MJ, Franco M, Martinez-Arán A, Segarra N, Tabarés-Seisdedos R, Vieta E, Purdon SE, Díez T, Rejas J, the Spanish Working Group in Cognitive Function: Spanish version of the screen for cognitive impairment in psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophr Res. 2008, 99: 139-148. 10.1016/j.schres.2007.09.012.
Rojo E, Pino O, Guilera G, Gómez-Benito J, Purdon SE, Crespo-Facorro B, Cuesta MJ, Franco M, Martínez-Arán A, Segarra N, Tabarés-Seisdedos R, Vieta E, Bernardo M, Mesa F, Rejas J, on behalf of the Spanish Working Group in Cognitive Function: Neurocognitive diagnosis and cut-off scores of the screen for cognitive impairment in psychiatry (SCIP-S). Schizophr Res. 2010, 116: 243-251. 10.1016/j.schres.2009.08.005.
Pino O, Guilera G, Gómez J, Rojo JE, Vallejo J, Purdon SE: Escala breve para evaluar el deterioro cognitivo en pacientes psiquiátricos. Psicothema. 2006, 18: 447-452.
Anastasi A, Urbina S: Psychological testing. 1997, NJ: Prentice Hall, 7
Kendall PC, Marrs-Garcia A, Nath SR, Sheldrick RC: Normative comparisons for the evaluation of clinical significance. J Consult Clin Psychol. 1999, 67: 285-299.
Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW: Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophren Res. 2004, 70: 175-186. 10.1016/j.schres.2003.10.009.
Iverson GL, Brooks BL, Haley GM: Interpretation of the RBANS in inpatient psychiatry: clinical normative data and prevalence of low scores for patients with schizophrenia. Appl Neuropsychol. 2009, 16: 31-41. 10.1080/09084280802644128.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Text Revision (DSM-IV TR). 2000, Washington DC: APA, 4
Kay SR, Opler LA, Fiszbein A: The positive and negative syndrome scale (PANSS). Rat Man Soc Behav Sci Doc. 1986, 17: 28-29.
Peralta V, Cuesta MJ: Escala del síndrome positivo y negativo en la esquizofrenia (PANSS), Manual de puntuación. 2004, Madrid: Janssen
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23: 56-62. 10.1136/jnnp.23.1.56.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978, 133: 429-435. 10.1192/bjp.133.5.429.
Lewis R: Should cognitive deficit a diagnostic criterion for schizophrenia?. J Psychiatry Neurosci. 2004, 29: 102-113.
Keefe RS, Fenton WS: How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr Bull. 2007, 33: 912-920. 10.1093/schbul/sbm046.
Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ, Malec JF: Mayo's Older Americans normative studies: Age- and IQ-adjusted norms for the auditory verbal learning test and the visual spatial learning test. Clin Neuropsychol. 2005, 19: 464-523. 10.1080/13854040590945193.
Choca JP, Krueger KR, de la Torre GG, Corral S, Garside D: Demographic adjustments for the Spanish version of the WAIS-III. Arch Clin Neuropsychol. 2009, 24: 619-629. 10.1093/arclin/acp049.
van Haren NE, Hulshoff Pol HE, Schnack HE, Cahn W, Brans R, Carati I, Rais M, Kahn RS: Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008, 63: 106-113. 10.1016/j.biopsych.2007.01.004.
Brans RG, Kahn RS, Schnack HG, van Baal GC, Posthuma D, van Haren NE, Lepage C, Lerch JP, Collins DL, Evans AC, Boomsma DI, Hulshoff Pol HE: Brain plasticity and intellectual ability are influenced by shared genes. J Neurosci. 2010, 30: 5519-5524. 10.1523/JNEUROSCI.5841-09.2010.
Schofield PW, Marder K, Dooneief G, Jacobs DM, Sano M, Stern Y: Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry. 1997, 154: 609-615.
Hohman TJ, Beason-Held LL, Lamar M, Resnick SM: Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011, 25: 125-130.
Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA: Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006, 59: 863-871. 10.1016/j.biopsych.2005.09.005.
Woodberry KA, Seidman LJ, Giuliano AJ, Verdi MB, Cook WL, McFarlane WR: Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr Res. 2010, 123: 188-198. 10.1016/j.schres.2010.06.021.
Zanelli J, Reichenberg A, Morgan K, Fearon P, Kravariti E, Dazzan P, Morgan C, Zanelli C, Demjaha A, Jones PB, Doody GA, Kapur S, Murray RM: Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry. 2010, 167: 78-85. 10.1176/appi.ajp.2009.09010118.
Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Færden A, Jo´nsdo´ttir H, Ringen PA, Opjordsmoen S, Melle I, Friis S, Andreassen OA: Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 2011, 37: 73-83. 10.1093/schbul/sbp034.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/13/127/prepub
Authors sincerely thanks Pfizer Spain for funding the study. Also, authors wish to thank participant psychiatrists for kindly collect data for analysis of this study.
Role of funding source
Data collection and analysis were funded by Pfizer Spain. Main analysis was conducted at the Universidad of Barcelona which received a grant from Pfizer Spain to carry out the statistical analysis. The funding body has no role in analysis of data. All authors had complete access to the data, participated in the analysis and/or interpretation of results, and drafted the manuscript.
Javier Rejas and Francisco Mesa are employees of Pfizer Spain, the body funding the original study sourcing data for this manuscript. All other authors declare that they have no conflicts of interests and none received payments or honoraria as a consequence of authorship for this manuscript.
This was a collaborative work, and the authors worked closely each other. All authors participated in the design of the original study or in the interpretation and analysis of data and all of them drafting and have approved the final version of manuscript. All authors were responsible for literature review and extraction of references, and also for taking the decision to submit the paper for publication.
About this article
Cite this article
Gómez-Benito, J., Guilera, G., Pino, Ó. et al. The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. BMC Psychiatry 13, 127 (2013) doi:10.1186/1471-244X-13-127
- Standardization data
- Bipolar I disorder